Calcitonin controls bone formation by inhibiting the release of sphingosine 1-phosphate from osteoclasts
Open accessThe DOI matches its Crossref record; 65 of the 65 references it cites were found in a registry or an index.
Abstract
The hormone calcitonin (CT) is primarily known for its pharmacologic action as an inhibitor of bone resorption, yet CT-deficient mice display increased bone formation. These findings raised the question about the underlying cellular and molecular mechanism of CT action. Here we show that either ubiquitous or osteoclast-specific inactivation of the murine CT receptor (CTR) causes increased bone formation. CT negatively regulates the osteoclast expression of Spns2 gene, which encodes a transporter for the signalling lipid sphingosine 1-phosphate (S1P). CTR-deficient mice show increased S1P levels, and their skeletal phenotype is normalized by deletion of the S1P receptor S1P 3 . Finally, pharmacologic treatment with the nonselective S1P receptor agonist FTY720 causes increased bone formation in wild-type, but not in S1P 3 -deficient mice. This study redefines the role of CT in skeletal biology, confirms that S1P acts as an osteoanabolic molecule in vivo and provides evidence for a pharmacologically exploitable crosstalk between osteoclasts and osteoblasts.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures







Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Calcr ϩ/Ϫ (hemizygous): high bone mass, increased bone formation.”
From The Activity of Peptides of the Calcitonin Family in Bone (2019) · cites this paper as [119]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Recently, procalcitonin has been shown to inhibit osteoclast differentiation in bone marrow cultures, and interestingly, this activity was not mediated by the calcitonin receptor (CTR) (119).”
From The Activity of Peptides of the Calcitonin Family in Bone (2019) · cites this paper as [119]
The cited source says what the claim attributes to it.
In the citing paper
“Similar to the previous models of CTR deficiency, the Calcr KO mice had high bone mass because of increased bone formation, a phenotype that was then reproduced in mice that had the gene deletion restricted to the osteoclast lineage.”
From The Activity of Peptides of the Calcitonin Family in Bone (2019) · cites this paper as [119]
The cited source says what the claim attributes to it.
In the citing paper
“The study found that the loss of CTR in osteoclasts increased the levels of sphingolipid transporter 2 (SPNS2), an exporter protein required for the secretion of sphingosine-1-phosphate (S1P), which is a potent inducer of bone formation.”
From The Activity of Peptides of the Calcitonin Family in Bone (2019) · cites this paper as [119]
The cited source says what the claim attributes to it.
In the citing paper
“Therefore, according to this study, calcitonin binding to CTR on osteoclasts inhibits the expression of SPNS2, causing a drop in S1P secretion and inhibition of osteoblast activity caused by the reduced levels of S1P (119).”
From The Activity of Peptides of the Calcitonin Family in Bone (2019) · cites this paper as [119]
3 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Parfitt, A. M., Drezner, M. K., Glorieux, F. H., Kanis, J. A., Malluche, H., Meunier, P. J., Ott, S. M., & Recker, R. R. (1987) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.5650020617 · Cited by 5,016
How many drug targets are there?
Overington, J. P., Al-Lazikani, B., & Hopkins, A. L. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2199 · Cited by 3,505
Bone Histomorphometry : Standardization of Nomenclature, Symbols, and Units
PARFITT, A. M., Drezner, M. K., Glorieux, F. H., Kanis, J. А., Malluche, H. H., Meunier, P. J., Ott, S. M., & Recker, R. R. (1987) · Journal of Bone and Mineral Research · Cited by 3,258
Osteoporosis: now and the future
Rachner, T. D., Khosla, S., & Hofbauer, L. C. (2011) · The Lancet · doi:10.1016/s0140-6736(10)62349-5 · Cited by 2,696
Self-citationConditional gene targeting in macrophages and granulocytes using LysMcre mice
Clausen, B. E., Burkhardt, C., Reith, W., Renkawitz, R., & Förster, I. (1999) · Transgenic Research · doi:10.1023/a:1008942828960 · Cited by 2,098
Schwenk, F., Baron, U., & Rajewsky, K. (1995) · Nucleic Acids Research · doi:10.1093/nar/23.24.5080 · Cited by 1,289
Fingolimod (FTY720): discovery and development of an oral drug to treat multiple sclerosis
Brinkmann, V., Billich, A., Baumruker, T., Heining, P., Schmouder, R., Francis, G., Aradhye, S., & Burtin, P. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3248 · Cited by 1,273
Skeletal remodeling in health and disease
Zaidi, M. (2007) · Nature Medicine · doi:10.1038/nm1593 · Cited by 1,069
Mechanism of Action of Oral Fingolimod (FTY720) in Multiple Sclerosis
Chun, J., & Hartung, H.-P. (2010) · Clinical Neuropharmacology · doi:10.1097/wnf.0b013e3181cbf825 · Cited by 796
Self-citationBidirectional ephrinB2-EphB4 signaling controls bone homeostasis
Zhao, C., Irie, N., Takada, Y., Shimoda, K., Miyamoto, T., Nishiwaki, T., Suda, T., & Matsuo, K. (2006) · Cell Metabolism · doi:10.1016/j.cmet.2006.05.012 · Cited by 777
Cited by
Kenkre, J., & Bassett, J. (2018) · Annals of Clinical Biochemistry: International Journal of Laboratory Medicine · doi:10.1177/0004563218759371 · Cited by 693
“By contrast, calcitonin-deficient mice show increased bone formation, and at physiological concentrations, calcitonin inhibits the actions of sphingosine-1phosphate, a coupling factor that links bone formation to resorption.(116,117)”
BackgroundUse of bone turnover markers in postmenopausal osteoporosis
Eastell, R., & Szulc, P. (2017) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(17)30184-5 · Cited by 594
Physiological Bone Remodeling: Systemic Regulation and Growth Factor Involvement
Siddiqui, J. A., & Partridge, N. C. (2016) · Physiology · doi:10.1152/physiol.00061.2014 · Cited by 534
“bone formation by inhibiting the release of sphingosine 1-phosphate (S1P) from osteoclasts (82).”
BackgroundAmylin: Pharmacology, Physiology, and Clinical Potential
Hay, D. L., Chen, S., Lutz, T. A., Parkes, D. G., & Roth, J. D. (2015) · Pharmacological Reviews · doi:10.1124/pr.115.010629 · Cited by 400
“Subsequent studies have developed mice with 94%–100% deletion of the calcitonin receptor, using the Cre-LoxP system, targeting exons 13 and 14 or exons 6 and 7 (Davey et al., 2008; Keller et al., 2014).”
BackgroundMethodUpdate on the pharmacology of calcitonin/CGRP family of peptides: IUPHAR Review 25
Hay, D. L., Garelja, M. L., Poyner, D. R., & Walker, C. S. (2018) · British Journal of Pharmacology · doi:10.1111/bph.14075 · Cited by 370
“…is a hormone produced by C cells of the thyroid, whose role is to reduce plasma calcium and promote bone formation (Findlay and Sexton, 2004), although CT-deficient mice show a paradoxical inhibition of bone formation due to enhanced sphingosine-1-phosphate production (Keller et al., 2014).”
BackgroundBreast cancer bone metastases: pathogenesis and therapeutic targets
Brook, N., Brook, E., Dharmarajan, A., Dass, C. R., & Chan, A. (2018) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2018.01.003 · Cited by 186
Targeting strategies for bone diseases: signaling pathways and clinical studies
Xu, H., Wang, W., Liu, X., Huang, W., Zhu, C., Xu, Y., Yang, H., Bai, J., & Geng, D. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01467-8 · Cited by 162
“7c), a nonspecific S1PR1 agonist, was also demonstrated to reverse bone loss in OVX mice.(183) These results indicate the potential to target S1PR for therapeutic interventions.”
BackgroundCurrent advances in regulation of bone homeostasis
Al‐Bari, M. A. A., & Mamun, A. A. (2020) · FASEB BioAdvances · doi:10.1096/fba.2020-00058 · Cited by 162
The Activity of Peptides of the Calcitonin Family in Bone
Naot, D., Musson, D. S., & Cornish, J. (2019) · Physiological Reviews · doi:10.1152/physrev.00066.2017 · Cited by 141
“Recently, procalcitonin has been shown to inhibit osteoclast differentiation in bone marrow cultures, and interestingly, this activity was not mediated by the calcitonin receptor (CTR) (119).”
BackgroundMethodInfluentialUnderstanding the local actions of lipids in bone physiology
During, A., Penel, G., & Hardouin, P. (2015) · Progress in Lipid Research · doi:10.1016/j.plipres.2015.06.002 · Cited by 148
“For example, inhibition of S1P release from osteoclasts by calcitonin, by down-regulating the gene expression of one S1P transporter, resulted in increased bone formation [187].”
BackgroundPiezo1 Inactivation in Chondrocytes Impairs Trabecular Bone Formation
Hendrickx, G., Fischer, V., Liedert, A., von Kroge, S., Haffner-Luntzer, M., Brylka, L., Pawlus, E., Schweizer, M., Yorgan, T., Baranowsky, A., et al. (2020) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.4198 · Cited by 131
“Louis, MO, USA) supplemented with 10% FCS (Hyclone Laboratories, Logan, UT, USA), 1% Pen/Strep (Gibco, Grand Island, NY, USA), 50 μg/mL ascorbic acid and 10mM β-glycerophosphate as described.((37)) After 2 days of differentiation, cells were serum-starved overnight and then treated for 6 hours with Yoda1 (5μM; Tocris…”
MethodSelf-citationSims, N. A. (2016) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2016.08.003 · Cited by 128
Targeting sphingosine-1-phosphate lyase as an anabolic therapy for bone loss
Weske, S., Vaidya, M., Reese, A., Lipinski, K. V. W., Keul, P., Bayer, J. K., Fischer, J. W., Flögel, U., Nelsen, J., Epple, M., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0005-y · Cited by 130
Self-citationOsteoporosis therapies and their mechanisms of action (Review)
Kim, B., Cho, Y., & Lim, W. (2021) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2021.10815 · Cited by 117
The critical interplay between bone resorbing and bone forming cells
Lerner, U. H., Kindstedt, E., & Lundberg, P. (2019) · Journal Of Clinical Periodontology · doi:10.1111/jcpe.13051 · Cited by 112
New insights into functions of the sphingosine-1-phosphate transporter SPNS2
Spiegel, S., Maczis, M. A., Maceyka, M. W., & Milstien, S. (2019) · Journal of Lipid Research · doi:10.1194/jlr.s091959 · Cited by 100
“calcitonin can also function as an inhibitor of bone formation (23).”
BackgroundThe underlying pathophysiology and therapeutic approaches for osteoporosis
Awasthi, H., Mani, D., Singh, D. R., & Gupta, A. K. (2018) · Medicinal Research Reviews · doi:10.1002/med.21504 · Cited by 91
Melatonin is a potential drug for the prevention of bone loss during space flight
Ikegame, M., Hattori, A., Tabata, M. J., Kitamura, K., Tabuchi, Y., Furusawa, Y., Maruyama, Y., Yamamoto, T., Sekiguchi, T., Matsuoka, R., et al. (2019) · Journal of Pineal Research · doi:10.1111/jpi.12594 · Cited by 89
The neuropeptide calcitonin gene-related peptide alpha is essential for bone healing
Appelt, J., Baranowsky, A., Jahn, D., Yorgan, T. A., Köhli, P., Otto, E., Farahani, S. K., Graef, F., Fuchs, M., Herrera, A., et al. (2020) · EBioMedicine · doi:10.1016/j.ebiom.2020.102970 · Cited by 95
“Osteoclast formation was quanti fi ed by TRAP activity staining as described previously [43].”
Self-citationWeivoda, M. M., Ruan, M. M., Pederson, L. G., Hachfeld, C. M., Davey, R. A., Zajac, J. D., Westendorf, J. J., Khosla, S., & Oursler, M. J. (2015) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.2586 · Cited by 86
“The role of osteoclast-derived sphingosine 1-phosphate (S1P) in promoting bone formation was further validated in studies by Keller and colleagues((38)) and Lotinun and colleagues.”
BackgroundDaponte, V., Henke, K., & Drissi, H. (2024) · eLife · doi:10.7554/elife.95083 · Cited by 96
“Similarly, the thyroid hormone calcitonin, which binds the transmembrane calcitonin receptor (CTR) on the osteoclast membrane, acts as a negative regulator of SPNS2 expression likely through phospholipase C signaling thereby reducing S1P secretion ( Keller et al., 2014 ).”
BackgroundGut microbiota and microbial metabolites for osteoporosis
Zheng, X.-Q., Wang, D.-B., Jiang, Y., & Song, C. (2024) · Gut Microbes · doi:10.1080/19490976.2024.2437247 · Cited by 97
Sphingolipid metabolism and its role in the skeletal tissues
Khavandgar, Z., & Murshed, M. (2014) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-014-1778-x · Cited by 94
“A recently published study showed that calcitonin, a thyroid-derived hormone, affects bone formation by regulating the release of S1P by osteoclasts [62].”
BackgroundSphingosine 1-phosphate signaling in bone remodeling: multifaceted roles and therapeutic potential
Meshcheryakova, A., Mechtcheriakova, D., & Pietschmann, P. (2017) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2017.1332180 · Cited by 74
“in a study addressing the impact of calcitonin on bone remodeling [89].”
BackgroundResultInfluentialChen, X., Zhu, X., Xiao, W., Liu, G., Feng, Y. P., Ding, J., & Li, R. (2015) · ACS Nano · doi:10.1021/acsnano.5b00456 · Cited by 71
Calcitonin and Bone Physiology: In Vitro, In Vivo, and Clinical Investigations
Xie, J., Guo, J., Kanwal, Z., Wu, M., Lv, X., Ibrahim, N. A., Li, P., Buabeid, M. A., Arafa, E. A., & Sun, Q. (2020) · International Journal of Endocrinology · doi:10.1155/2020/3236828 · Cited by 83
“In recent studies, it was reported that osteoclast differentiation was inhibited by procalcitonin in cultures prepared from bone marrow, and surprisingly, the calcitonin receptor did not play any role to induce this process [23].”
BackgroundZheng, S., Zhou, C., Yang, H., Li, J., Feng, Z., Liao, L., & Li, Y. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.826660 · Cited by 77
“It has a major influence on individuals associated with high morbidity and mortality (5).”
BackgroundThe role of sphingosine-1-phosphate in bone remodeling and osteoporosis
Grewe, J. M., Knapstein, P., Donat, A., Jiang, S., Smit, D. J., Xie, W., & Keller, J. (2022) · Bone Research · doi:10.1038/s41413-022-00205-0 · Cited by 76
“Once activated, downstream signaling pathways lead to altered migration, adhesion, survival, proliferation and angiogenesis.23 While S1PR1–3 are expressed in various cell types, S1PR4 and S1PR5 expression is restricted to lymphoid and hematopoietic tissues, as well as the central nervous system and the spleen, respect…”
BackgroundMethodSelf-citationCrosstalk Between the Neuroendocrine System and Bone Homeostasis
Zhao, Y., Peng, X., Wang, Q., Zhang, Z., Wang, L., Xu, Y., Yang, H., Bai, J., & Geng, D. (2023) · Endocrine Reviews · doi:10.1210/endrev/bnad025 · Cited by 78
Chen, C., Jung, B., & Kim, W. K. (2019) · Poultry Science · doi:10.3382/ps/pez111 · Cited by 66
Estrogen receptors in breast and bone: from virtue of remodeling to vileness of metastasis
Bado, I., Gugala, Z., Fuqua, S. A. W., & Zhang, X. (2017) · Oncogene · doi:10.1038/onc.2017.94 · Cited by 71
Johnson, R. W., McGregor, N. E., Brennan, H. J., Crimeen‐Irwin, B., Poulton, I. J., Martin, T., & Sims, N. (2015) · Bone · doi:10.1016/j.bone.2015.08.005 · Cited by 56
van der Burgh, A. C., de Keyser, C. E., Zillikens, M. C., & Stricker, B. H. C. (2021) · Drugs · doi:10.1007/s40265-021-01625-8 · Cited by 64
Sun, H., Lu, N., Luo, X., Zhao, L., & Liu, J. (2015) · Journal of Diabetes · doi:10.1111/1753-0407.12282 · Cited by 59
“A recent study provided further evidence that calcitonin functions physiologically as an inhibitor of bone formation despite its pharmacological inhibition of bone resorption.(25) Thus, measuring changes in circulating calcitonin concentrations, as well as bone formation and bone resorption markers, after liraglutide…”
BackgroundFinely-Tuned Calcium Oscillations in Osteoclast Differentiation and Bone Resorption
Okada, H., Okabe, K., & Tanaka, S. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms22010180 · Cited by 55
“In a recent paper, calcitonin was shown to induce bone formation by interrupting sphingosine 1-phosphate release from osteoclasts [112].”
BackgroundThe Role of Sphingolipid Metabolism in Bone Remodeling
Tang, Q., Liao, L., & Tian, W. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.752540 · Cited by 59
Clarke, M. V., Russell, P. K., Findlay, D. M., Sastra, S., Anderson, P. H., Skinner, J. P., Atkins, G. J., Zajac, J. D., & Davey, R. A. (2015) · Endocrinology · doi:10.1210/en.2015-1345 · Cited by 54
“Specifically, the 2 intriguing actions of calcitonin identified in these studies are its actions to (1) inhibit bone formation (10, 11) by inhibiting the release of sphingosine 1-phosphate from osteoclasts (12) and (2) to protect the skeleton during calcium stress, in particular during hypercalcemia (13) mediated prim…”
BackgroundGlucose Metabolism in Osteoblasts in Healthy and Pathophysiological Conditions
Donat, A., Knapstein, P.-R., Jiang, S., Baranowsky, A., Ballhause, T.-M., Frosch, K.-H., & Keller, J. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22084120 · Cited by 53
Self-citationSassoli, C., Pierucci, F., Zecchi‐Orlandini, S., & Meacci, E. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20225545 · Cited by 56
“SPNS2 represents the master regulator of the secretion of S1P in most mammalian cells exerting a special function in the development and homing of immune cells and in bone homeostasis [47,48].”
BackgroundShiwaku, Y., Neff, L., Nagano, K., Takeyama, K., de Bruijn, J. D., Dard, M. M., Gori, F., & Baron, R. (2015) · PLoS ONE · doi:10.1371/journal.pone.0132903 · Cited by 53
“In OBs, S1P interacts with S1P receptors and promotes OB migration and survival [19,20,46,47].”
BackgroundYu, F.-Y., Xie, C., Sun, J., Peng, W., & Huang, X. (2018) · Life Sciences · doi:10.1016/j.lfs.2018.03.042 · Cited by 53
Hsiao, C.-Y., Chen, T.-H., Chu, T.-H., Ting, Y.-N., Tsai, P., & Shyu, J. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.00613 · Cited by 55
“(8) through experiments on a new strain of viable global Calcr KO mice, which were generated by applying a specific technique to knockout the expression of CTR.”
BackgroundMethodChen, M., Huang, L. F., Shen, X., Li, M., Luo, Z. Y., Cai, K., & Hu, Y. (2020) · Acta Biomaterialia · doi:10.1016/j.actbio.2020.01.029 · Cited by 52
Li, B., Wu, P., Fu, W., Xiong, Y., Zhang, L., Gao, Y., Deng, G., Zong, S., & Zeng, G. (2019) · Rejuvenation Research · doi:10.1089/rej.2018.2126 · Cited by 48
“…pathway, providing a new mechanism for the inhibition of osteoclastogenesis by PSP. miRNAs are a large class of single-stranded, endogenous, noncoding RNAs of 19–26 nt, which are widely expressed in a variety of biological races and are encoded by genes and introns encoding the intergenic spacers.”
Coester, B., Koester-Hegmann, C., Lutz, T. A., & Le Foll, C. (2020) · Diabetes · doi:10.2337/db19-0849 · Cited by 45
“;MGI:5751436) (frozen sperm kindly provided by Drs. Jean-Pierre David and Thorsten Shinke, UniversityMedical Center Hamburg) (17).”
BackgroundMethodInfluentialS1P-S1PR1 Signaling: the “Sphinx” in Osteoimmunology
Xiao, L., Zhou, Y., Friis, T., Beagley, K. W., & Xiao, Y. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01409 · Cited by 52
“Accordingly, hormone calcitonin (CT) has been found to block S1P secretion of osteoclast via SPNS2 inhibition, which consequently results in decreased bone formation in vivo in a S1PR3-dependent manner (55).”
BackgroundBioactivity, Molecular Mechanism, and Targeted Delivery of Flavonoids for Bone Loss
Sharma, A. R., Lee, Y., Bat-Ulzii, A., Chatterjee, S., Bhattacharya, M., Chakraborty, C., & Lee, S. (2023) · Nutrients · doi:10.3390/nu15040919 · Cited by 56
Al-Yatama, F., AlOtaibi, F., Al‐Bader, M., & Al-Shoumer, K. A. S. (2019) · International Journal of Endocrinology · doi:10.1155/2019/6794837 · Cited by 53
Sartawi, Z., Schipani, E., Ryan, K. B., & Waeber, C. (2017) · Pharmacological Research · doi:10.1016/j.phrs.2017.08.013 · Cited by 51
Li, M., Fu, S., Cai, Z., Li, D., Liu, L., Deng, D., Jin, R., & Ai, H. (2021) · Regenerative Biomaterials · doi:10.1093/rb/rbab027 · Cited by 44
“SPIO@15HA nanocomposites up-regulated p62 expression in preosteoclasts and activated osteogenesis associated signaling pathways in MSC During the process of osteoclast maturation, several marker genes play the pivotal roles including: RANK, the initial signal of osteoclast formation [42, 43]; c-Src, essential in osteo…”
BackgroundHigashi, K., Matsuzaki, E., Hashimoto, Y., Takahashi‐Yanaga, F., Takano, A., Anan, H., Hirata, M., & Nishimura, F. (2016) · Bone · doi:10.1016/j.bone.2016.09.003 · Cited by 43
Huang, L. F., Luo, Z. Y., Hu, Y., Shen, X., Li, M., Li, L., Zhang, Y., Yang, W., Liu, P., & Cai, K. (2016) · Journal of Biomedical Materials Research Part A · doi:10.1002/jbm.a.35667 · Cited by 39
Role of Biomolecules in Osteoclasts and Their Therapeutic Potential for Osteoporosis
Zhao, X., Patil, S., Xu, F., Lin, X., & Qian, A. (2021) · Biomolecules · doi:10.3390/biom11050747 · Cited by 41
“This gene encodes a transporter for the signaling lipid sphingosine 1-phosphate (S1P), which couples bone formation to bone resorption [74].”
BackgroundPark‐Min, K., & Lorenzo, J. A. (2022) · Bone · doi:10.1016/j.bone.2022.116576 · Cited by 39
Genesis of Osteoclasts on Calcium Phosphate Ceramics and its Role in Material-Induced Bone Formation
Nie, Z., Hu, Z., Guo, X., Xiao, Y. M., Liu, X., de Bruijn, J. D., Bao, C., & Yuan, H. (2022) · Acta Biomaterialia · doi:10.1016/j.actbio.2022.11.005 · Cited by 38
Jahn, D., Knapstein, P. R., Otto, E., Köhli, P., Sevecke, J., Graef, F., Graffmann, C., Fuchs, M., Jiang, S., Rickert, M., et al. (2024) · Science Translational Medicine · doi:10.1126/scitranslmed.adk9129 · Cited by 44
Self-citationZhu, M., Sun, B., Saar, K., Simpson, C. A., Troiano, N. W., Dallas, S. L., Tiede-Lewis, L. M., Nevius, E., Pereira, J. P., Weinstein, R. S., et al. (2015) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.2733 · Cited by 34
“In one, increased expression of the rate-limiting enzyme for S1P synthesis, SPHK1, is responsible for the increase in S1P production and in the other, increased expression of the cellular S1P exporter, SPNS2, is increased.((28,30)) We examined expression of both of these in osteoclasts isolated from DKO mice and found…”
BackgroundMethodJamal, A. E., Briolay, A., Mebarek, S., Goff, B. L., Blanchard, F., Magne, D., Brizuela, L., & Bougault, C. (2019) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.3844 · Cited by 36
“Regarding the bone cells, it was already known that osteoblasts and osteoclasts can produce S1P.”
BackgroundPharmacological diversity among drugs that inhibit bone resorption
Russell, R. G. G. (2015) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2015.05.005 · Cited by 36
The Lysosomal Protein Arylsulfatase B Is a Key Enzyme Involved in Skeletal Turnover
Pohl, S., Angermann, A., Jeschke, A., Hendrickx, G., Yorgan, T. A., Makrypidi‐Fraune, G., Steigert, A., Kühn, S. C., Rolvien, T., Schweizer, M., et al. (2018) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.3563 · Cited by 33
“Here we compared four stages during ex vivo osteoclastogenesis of wildtype bone marrow cells, thereby identifying Calcr (encoding the calcitonin receptor) (41) as the most strongly induced transcript between day 1 and day 7 of differentiation (Fig.”
BackgroundSelf-citationSpatiotemporally controlled calcitonin delivery: Long-term and targeted therapy of skeletal diseases
Yu, P., Liu, Y., Xie, J., & Li, J. (2021) · Journal of Controlled Release · doi:10.1016/j.jconrel.2021.08.056 · Cited by 37
Behler-Janbeck, F., Baranowsky, A., Yorgan, T. A., Jaeckstein, M. Y., Worthmann, A., Fuh, M. M., Gunasekaran, K., Tiegs, G., Amling, M., Schinke, T., et al. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1392418 · Cited by 38
Self-citationInvolvement of sphingosine kinase/sphingosine 1-phosphate metabolic pathway in spondyloarthritis
Bougault, C., Jamal, A. E., Briolay, A., Mebarek, S., Boutet, M., Garraud, T., Goff, B. L., Blanchard, F., Magne, D., & Brizuela, L. (2017) · Bone · doi:10.1016/j.bone.2017.07.002 · Cited by 36
Weske, S., Vaidya, M., Lipinski, K. V. W., Keul, P., Kristina, M., Burkhart, C., Haberhauer, G., Heusch, G., & Levkau, B. (2019) · Bone · doi:10.1016/j.bone.2019.04.015 · Cited by 36
Self-citationSphingosine‐1‐phosphate (S1P) receptors: Promising drug targets for treating bone‐related diseases
Zhang, L., Dong, Y., Wang, Y., Hu, W., Dong, S., & Chen, Y. (2020) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.15155 · Cited by 37
High Bone Turnover in Mice Carrying a Pathogenic Notch2 Mutation Causing Hajdu-Cheney Syndrome
Vollersen, N., Hermans‐Borgmeyer, I., Cornils, K., Fehse, B., Rolvien, T., Triviai, I., Jeschke, A., Oheim, R., Amling, M., Schinke, T., et al. (2017) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.3283 · Cited by 28
“For bone histology, the lumbar vertebral bodies L1 to L4 and the left tibia of each mouse were dehydrated in ascending alcohol concentrations and then embedded in methylmetacrylate as described previously.((21))”
MethodSelf-citationInoue, T., Kohno, M., Nagahara, H., Murakami, K., Sagawa, T., Kasahara, A., Kaneshita, S., Kida, T., Fujioka, K., Wada, M., et al. (2019) · PLoS ONE · doi:10.1371/journal.pone.0218090 · Cited by 29
Baranowsky, A., Appelt, J., Kleber, C., Lange, T., Ludewig, P., Jahn, D., Pandey, P., Keller, D. B., Rose, T., Schetler, D., et al. (2020) · Critical Care Medicine · doi:10.1097/ccm.0000000000004731 · Cited by 32
Self-citationGuo, X., Xue, M., Chen, F., Guo, Q., Zhou, X., Lin, H., & Chen, Y. (2021) · Biomaterials · doi:10.1016/j.biomaterials.2021.121300 · Cited by 29
Parathyroid hormone independent hypercalcemia in adults
Bollerslev, J., Pretorius, M., & Heck, A. (2018) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2018.06.005 · Cited by 31
Skeletal deterioration in COL2A1-related spondyloepiphyseal dysplasia occurs prior to osteoarthritis
Rolvien, T., Yorgan, T. A., Kornak, U., Hermans‐Borgmeyer, I., Mundlos, S., Schmidt, T., Niemeier, A., Schinke, T., Amling, M., & Oheim, R. (2020) · Osteoarthritis and Cartilage · doi:10.1016/j.joca.2019.12.011 · Cited by 30
Self-citationMaleitzke, T., Hildebrandt, A., Dietrich, T., Appelt, J., Jahn, D., Otto, E., Zocholl, D., Baranowsky, A., Duda, G. N., Tsitsilonis, S., et al. (2021) · iScience · doi:10.1016/j.isci.2021.103689 · Cited by 28
“Contrary to the reported osteoprotective effects of teleost CT through an inhibition of osteoclast activity (Karsdal et al., 2008), our group could previously show that endogenous CT suppresses bone formation through the inhibition of S1P secretion from osteoclasts (Keller et al., 2014).”
BackgroundResultSelf-citationViral depletion of calcitonin receptors in the area postrema: A proof-of-concept study
Coester, B., Foll, C. L., & Lutz, T. A. (2020) · Physiology & Behavior · doi:10.1016/j.physbeh.2020.112992 · Cited by 24
Mice lacking plastin-3 display a specific defect of cortical bone acquisition
Yorgan, T. A., Sari, H., Rolvien, T., Windhorst, S., Failla, A. V., Kornak, U., Oheim, R., Amling, M., & Schinke, T. (2019) · Bone · doi:10.1016/j.bone.2019.115062 · Cited by 26
Self-citationBiological function of SPNS2: From zebrafish to human
Zhu, X., Ren, K., Zeng, Y.-Z., Zheng, Z., & Yi, G.-H. (2018) · Molecular Immunology · doi:10.1016/j.molimm.2018.08.025 · Cited by 25
Calcitonin Physiology, Saved by a Lysophospholipid
Martin, T. J., & Sims, N. A. (2015) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.2449 · Cited by 21
“A recent report in Nature Communications(1) provides further impetus to the idea that despite its pharmacologic inhibition of bone resorption, calcitonin also functions physiologically as an inhibitor of bone formation.”
BackgroundInfluentialCui, M., Göbel, V., & Zhang, H. (2021) · Biological reviews/Biological reviews of the Cambridge Philosophical Society · doi:10.1111/brv.12798 · Cited by 25
“, 2001), however, 8-month-old S1pr3-deficient mice showed osteopenia and reduced bone formation (Keller et al., 2014).”
BackgroundSeal, A., Hughes, M., Wei, F., Pugazhendhi, A. S., Ngo, C., Ruiz, J., Schwartzman, J. D., & Coathup, M. J. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25053024 · Cited by 23
“All S1P receptors with the exception of S1PR 5 have been detected in bone marrow-derived macrophages and differentiating osteoclasts [171,172].”
BackgroundIncreased sphingosine-1-phosphate production in response to osteocyte mechanotransduction
Dobrosak, C., & Gooi, J. H. (2017) · Bone Reports · doi:10.1016/j.bonr.2017.10.002 · Cited by 24
“Keller et al. proposed that increased bone formation seen in Calcr−/− mice was due to locally increased S1P concentrations resulting from increased Spns2-mediated transport (Keller et al., 2014).”
BackgroundWang, J., Cheng, Y., Yang, S., An, M., Zhang, H., Chen, H., & Yang, L. (2019) · Frontiers in Endocrinology · doi:10.3389/fendo.2019.00700 · Cited by 24
“CT is a hormone that increases both calcium and phosphate exudation via the kidney and causes further wastage of the calcium stored in bone (20).”
BackgroundBaranowsky, A., Jahn, D., Jiang, S., Yorgan, T. A., Ludewig, P., Appelt, J., Albrecht, K. K., Otto, E., Knapstein, P., Donat, A., et al. (2022) · Bone Research · doi:10.1038/s41413-021-00172-y · Cited by 25
“This observation is in line with our previous findings, where we demonstrated that CTR exhibits an S1P-dependent, inhibitory effect on the bone formation rate through its expression in osteoclasts.(25) In contrast, Calca-deficient mice, which lack ProCT, exhibit excessive bone resorption during iPTH treatment.”
BackgroundMethodResultInfluentialSelf-citationGeißler, S., Textor, M., Stumpp, S., Seitz, S. A., Lekaj, A., Brunk, S., Klaassen, S., Schinke, T., Klein, C., Mundlos, S., et al. (2018) · PLoS ONE · doi:10.1371/journal.pone.0198510 · Cited by 24
Self-citationThe role of SphK/S1P/S1PR signaling pathway in bone metabolism
Xu, X., Han, Y., Zhu, T., Fan, F., Wang, X., Liu, Y., & Luo, D. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.115838 · Cited by 21
Pascual-García, S., Martínez-Peinado, P., Pujalte-Satorre, C., Navarro‐Sempere, A., Esteve-Girbés, J., López-Jaén, A. B., Javaloyes-Antón, J., Cobo, R., Navarro-Blasco, F. J., & Sempere-Ortells, J. M. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25031506 · Cited by 19
“Additionally, they also express vitronectin receptors [50] and calcitonin receptors [51].”
BackgroundTsukamoto, M., Menuki, K., Murai, T., Hatakeyama, A., Takada, S., Furukawa, K., & Sakai, A. (2016) · Bone · doi:10.1016/j.bone.2016.01.025 · Cited by 19
Lipp, L., Sharma, D., Banerjee, A., & Singh, J. (2019) · ACS Omega · doi:10.1021/acsomega.8b02781 · Cited by 19
G protein-coupled receptors as anabolic drug targets in osteoporosis
Diepenhorst, N. A., Rueda, P., Cook, A. E., Pastoureau, P., Sabatini, M., & Langmead, C. J. (2017) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2017.10.015 · Cited by 20
“Osteoclasts are known to enhance S1P production when stimulated by RANK-L (Keller et al., 2014).”
BackgroundInfluentialWang, H., Li, T., Wang, X., Guan, Y., Jiang, Y., Chen, S., Zou, S., & Duan, P. (2021) · Clinical Oral Investigations · doi:10.1007/s00784-021-04084-3 · Cited by 18
Wei, Y., Ye, Q., Tang, Z., Tian, G., Zhu, Q., Gao, H., Wang, D., & Cao, Z. (2016) · Archives of Oral Biology · doi:10.1016/j.archoralbio.2016.11.014 · Cited by 21
Maleitzke, T., Hildebrandt, A., Weber, J., Dietrich, T., Appelt, J., Jahn, D., Zocholl, D., Baranowsky, A., Duda, G. N., Tsitsilonis, S., et al. (2020) · Rheumatology · doi:10.1093/rheumatology/keaa711 · Cited by 20
Self-citationHildebrandt, A., Dietrich, T., Weber, J., Günderoth, M. M., Zhou, S., Fleckenstein, F. N., Jiang, S., Winkler, T., Duda, G. N., Tsitsilonis, S., et al. (2023) · Arthritis Research & Therapy · doi:10.1186/s13075-023-03215-3 · Cited by 17
“RNA isolation and reverse transcription to complementary DNA (cDNA) were conducted as previously reported [26].”
MethodSelf-citationLademann, F., Tsourdi, E. A., Rijntjes, E., Köhrle, J., Hofbauer, L. C., Heuer, H., & Rauner, M. (2020) · Thyroid · doi:10.1089/thy.2019.0271 · Cited by 16
Self-citationCalcitonin receptor antibody validation and expression in the rodent brain
Hendrikse, E. R., Rees, T. A., Tasma, Z., Foll, C. L., Lutz, T. A., Siow, A., Wookey, P. J., Walker, C. S., & Hay, D. L. (2022) · Cephalalgia · doi:10.1177/03331024221084029 · Cited by 16
The role of sphingosine-1-phosphate signaling pathway in cementocyte mechanotransduction
Wang, H., Li, T., Wang, X., Yin, X., Zhao, N., Zou, S., Duan, P., & Bonewald, L. F. (2020) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2020.01.003 · Cited by 16
Hdac3 regulates bone modeling by suppressing osteoclast responsiveness to RANKL
Molstad, D. H. H., Mattson, A. M., Begun, D. L., Westendorf, J. J., & Bradley, E. W. (2020) · Journal of Biological Chemistry · doi:10.1074/jbc.ra120.013573 · Cited by 16
Differential effects of Calca-derived peptides in male mice with diet-induced obesity
Bartelt, A., Jeschke, A., Müller, B., Gaziano, I., Morales, M., Yorgan, T. A., Heckt, T., Heine, M., Gagel, R. F., Emeson, R. B., et al. (2017) · PLoS ONE · doi:10.1371/journal.pone.0180547 · Cited by 16
Self-citationSphingosine‐1‐Phosphate Modulates the Effect of Estrogen in Human Osteoblasts
Tantikanlayaporn, D., Tourkova, I. L., Larrouture, Q. C., Luo, J., Piyachaturawat, P., Witt, M. R., Blair, H. C., & Robinson, L. J. (2018) · JBMR Plus · doi:10.1002/jbm4.10037 · Cited by 14
“The expression ALP in the E2- and S1Ptreated group were higher than the control, as found in whole 9 cm((2)) cultures with alkaline phosphatase staining (Fig.”
BackgroundDeluca, A., Wagner, A., Heimel, P., Deininger, C., Wichlas, F., Redl, H. R., Rohde, E., Tempfer, H., Gimona, M., & Traweger, A. (2024) · Stem Cell Research & Therapy · doi:10.1186/s13287-024-03755-8 · Cited by 14
“The poor healing of such fractures is associated with a significantly increased patient morbidity and mortality [4].”
Evidence for altered osteoclastogenesis in splenocyte cultures from Cyp27b1 knockout mice
Reinke, D. C., Kogawa, M., Barratt, K. R., Morris, H. A., Anderson, P., & Atkins, G. J. (2015) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2015.11.015 · Cited by 13
Sphingomyelin Phosphodiesterase 3 Enhances Cytodifferentiation of Periodontal Ligament Cells
Miyauchi, S., Kitagaki, J., Masumoto, R., Imai, A., Kobayashi, K., Nakaya, A., Kawai, S., Fujihara, C., Asano, Y., Yamashita, M., et al. (2016) · Journal of Dental Research · doi:10.1177/0022034516677938 · Cited by 13
“FTY720, an agonist of S1P, increases BMP-2-induced calcified nodule formation in C2C12 cells in vitro (Sato et al. 2012) and the mouse trabecular bone volume in vivo (Keller et al. 2014).”
Background
Metadata
- Authors
- Keller, J., Catala-Lehnen, P., Huebner, A. K., Jeschke, A., Heckt, T., Lueth, A., Krause, M., Koehne, T., Albers, J., Schulze, J., Schilling, S., Haberland, M., Denninger, H., Neven, M., Hermans-Borgmeyer, I., Streichert, T., Breer, S., Barvencik, F., Levkau, B., Rathkolb, B., Wolf, E., Calzada-Wack, J., Neff, F., Gailus-Durner, V., Fuchs, H., de Angelis, M. H., Klutmann, S., Tsourdi, E., Hofbauer, L. C., Kleuser, B., Chun, J., Schinke, T., & Amling, M.
- Affiliations
- University Medical Center Hamburg-Eppendorf (DE)
- University of Potsdam (DE)
- Essen University Hospital (DE)
- Helmholtz Munich (DE)
- Ludwig-Maximilians-Universität München (DE)
- Scripps Research Institute (US)
- Corresponding author
- Amling, Michael
- ORCID
- Venue
- Nature Communications
- Published
- 2014-10-21
- Volume
- 5
- Issue
- 1
- Pages
- 5215-5215
- ISSN
- 2041-1723 (ISSN-L)
- PMC
- PMC4205484
- OpenAlex
- W1980751002
- Semantic Scholar
- e2f2d551f2624d9e90a89e2ee5d3017852508fd9
- Cited by
- 211
- References
- 64
- Citations by year
- 2026: 16 · 2025: 9 · 2024: 16 · 2023: 13 · 2022: 10 · 2021: 27 · 2020: 24 · 2019: 29 · 2018: 16 · 2017: 22 · 2016: 12 · 2015: 15 · 2014: 2
- FWCI
- 6.97
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Nature Communications (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Open access LMU (Ludwid Maxmilian's Universitat Munchen) (submittedVersion)
- publish.UP (University of Potsdam) (submittedVersion)
- mediaTUM (Technical University of Munich) (submittedVersion, other-oa)
- Site cant be reached (submittedVersion)
- OpenAgrar (submittedVersion)
- Funders
- INFRAFRONTIER (01KX1012)
- Deutsche Forschungsgemeinschaft (AM103/15-1, DA019674, 01KX1012)
- Bundesministerium für Bildung und Forschung (01GS0850, 01KX1012, 01GS0851)
- National Institutes of Health (5r01da019674-05, DA019674)
- National Institute on Drug Abuse (DA019674, R01-DA019674)
- National Institute on Deafness and Other Communication Disorders (DC009505, R21DC009505)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Bone Metabolism and Diseases
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Sphingolipid Metabolism and Signaling
- Health Sciences › Medicine › Orthopedics and Sports Medicine › Bone health and osteoporosis research
- Keywords
- calcitonin, calcitonin receptor, bone formation, osteoclasts, sphingosine-1-phosphate, S1P3 receptor, SPNS2, fingolimod, bone resorption, skeletal phenotype
- MeSH terms
- Alleles, Animals, Bone and Bones, Calcitonin, Crosses, Genetic, Female, Lysophospholipids, Mice, Inbred C57BL, Mice, Transgenic, Osteoblasts, Osteoclasts, Osteogenesis, Osteoporosis, Phenotype, Sphingosine, Signal Transduction, Porosity, Collagenases, Receptors, Calcitonin, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.